Comparative Pharmacology
Head-to-head clinical analysis: ALDORIL 25 versus VALTURNA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDORIL 25 versus VALTURNA.
ALDORIL 25 vs VALTURNA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Valsartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the AT1 receptor, reducing vasoconstriction and aldosterone secretion. Aliskiren is a direct renin inhibitor that decreases renin activity, lowering angiotensin I and II levels.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
One capsule orally once daily; dose depends on prior ARB or ACEi therapy: for patients not on an ARB or ACEi, start with 80/5 mg; for patients switching from an ARB, start with 160/5 mg; dose can be titrated to 160/5 mg or 320/10/12.5 mg based on BP response.
None Documented
None Documented
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Aliskiren: terminal half-life ~24 hours (range 23-28 h), supports once-daily dosing; Valsartan: terminal half-life ~6 hours (range 5-9 h), but clinical effect persists >24 h due to sustained AT1 receptor blockade.
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
Aliskiren: 78-90% of absorbed dose excreted unchanged via biliary/fecal route (hepatic), ~2.2% renal; Valsartan: 83% excreted unchanged in feces via bile, 13% renal.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination